Patient demographics stratified as per response to anti-interleukin (IL)-5 monoclonal antibody (mAb) treatment
| Responders | Nonresponders | p-value¶ | |||
| Observed sample size# | Statistic | Observed sample size | Statistic | ||
| Subjects n | 143 | 107 | |||
| Male | 143 | 77 (54) | 107 | 54 (50) | 0.688 |
| Age years | 143 | 57±13.9 | 107 | 54±12.6 | 0.119 |
| BMI kg·m−2 | 134 | 29.0±6.1 | 104 | 29.1±6.1 | 0.840 |
| Oral corticosteroids (prednisone) | 143 | 71 (50) | 107 | 70 (65) | 0.018* |
| Dose of prednisone mg·day−1 | 71 | 11.3±6.8 | 70 | 13.8±10.1 | 0.087 |
| Duration of prednisone years | 45 | 6.55±5.3 | 55 | 8.01±7.1 | 0.245 |
| Asthma onset in adulthood | 112 | 90 (80) | 90 | 80 (89) | 0.145 |
| Inhaled corticosteroid+ μg·day−1 | 143 | 1500 (1000–3000) | 107 | 1500 (1000–3000) | 0.653 |
| Baseline FEV1 % predicted | 141 | 66.8±18.8 | 106 | 64.9±20.0 | 0.452 |
| Previous biologic use | 141 | 54 (38) | 106 | 52 (49) | 0.118 |
| Lymphopenia | 137 | 70 (51) | 106 | 63 (59) | 0.244 |
| Atopy§ | 103 | 55 (53) | 84 | 55 (65) | 0.128 |
| Presence of sinus diseaseƒ | 141 | 65(46) | 107 | 66 (62) | 0.021* |
| Pre blood eosinophils ×109·L−1 | 140 | 0.56±0.5 | 106 | 0.57±0.7 | 0.909 |
| Pre sputum eosinophils % of total cell count | 91 | 21.7±22.7 | 69 | 18.7±19.5 | 0.376 |
| Exacerbations in preceding year | 143 | 2.154±1.9 | 107 | 2.4±2 | 0.324 |
| Exacerbations in preceding year | 143 | 2 (0–12) | 107 | 2 (0–9) | 0.354 |
Data are presented as n, n (% of observed sample size), mean±sd or median (range), unless otherwise stated. Out of the 250 patients, 55 were recruited from the McGill University Health Centre, 88 from the Firestone Institute for Respiratory Health, St. Joseph's Healthcare (McMaster University), 47 from Sacré-Coeur hospital of Montreal and 60 from Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec (Université Laval) were included in the final analysis. BMI: body mass index; FEV1: forced expiratory volume in 1 s; Pre: pretreatment baseline values. #: the data available for each variable across sites; ¶: two-sided t-test for continuous variables, Chi-squared test for dichotomous variables; +: presented as fluticasone propionate-equivalent; §: assessed as positive skin-prick test to common aeroallergens, or specific immunoglobulin E positivity in the sera; ƒ: defined as physician-reported or computed tomography evidence of chronic sinusitis with or without polyps. *: indicates significant difference p<0.05.